PTK6 Inhibitors May Target Endocrine Therapy-Resistant ER+ Breast Cancer Interview with:

Hanna Irie MD PhD Assistant Professor Oncology Mount Sinai Health System 

Dr. Irie

Hanna Irie MD PhD, senior author
Assistant Professor of Medicine
(Hematology and Medical Oncology) and Oncological Sciences at The Tisch Cancer Institute,
Icahn School of Medicine at Mount Sinai What is the background for this study? What are the main findings?

Response: Our study identified PTK6 as a critical gene regulating survival of ER+ breast cancer cells.

PTK6 inhibition also suppresses growth and survival of ER+ breast cancer cells that are resistant to the effects of therapies commonly used to treat patient ER+ breast cancers, making PTK6 an attractive candidate therapeutic target for these resistant cancers. What should clinicians and patients take away from your report?

Response:     Additional studies validating PTK6 as a therapeutic target for ER+ breast cancer, the most common breast cancer subtype, are underway and could lead to a novel approach to treating these cancers. What recommendations do you have for future research as a result of this study?

Response:    We are planning to study the effects of different types of PTK6 inhibitors in cell line and animal models, which if successful could be translated clinically. Thank you for your contribution to the community.


PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells
Koichi Ito, Sun Hee Park, Igor Katsyv, Weijia Zhang, Carmine De Angelis, Rachel Schiff & Hanna Y. Irie

npj Breast Cancer 3, Article number: 45 (2017)

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions. 

[wysija_form id=”1″]